Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1*

[News]

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.

More... (http://www.news-medical.net/news/20091130/Minerva-Biotechnologies-grants-Clarient-exclusive-commercializing-rights-to-its-MUC1-diagnostic-test.aspx)